Gritstone bio, Inc. Common Stock
GRTS
GRTS was delisted on the 21st of October, 2024.
54 hedge funds and large institutions have $244M invested in Gritstone bio, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 18 increasing their positions, 17 reducing their positions, and 8 closing their positions.
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
4% more funds holding
Funds holding: 52 → 54 (+2)
6% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 17
12% less capital invested
Capital invested by funds: $279M → $244M (-$34.7M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Casdin Capital
New York
|
+$5.35M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
+$2.63M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$1.44M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
+$1.13M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$808K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$8.43M |
| 2 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
-$1.25M |
| 3 |
LCM
Laurion Capital Management
New York
|
-$1.18M |
| 4 |
PCM
Prelude Capital Management
New York
|
-$440K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$262K |
GRTS Hedge Fund Activity: Q1 2019 in Review
54 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Gritstone bio, Inc. Common Stock (GRTS) for Q1 2019, worth a combined $244M — down 12% from $279M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new GRTS positions and 8 closed out — a net gain of 2 holders — while 18 added to existing stakes and 17 trimmed.
The largest buyer was Casdin Capital, adding an estimated $5.35M. The largest seller was PFM Health Sciences, cutting an estimated $8.43M.
- 54 institutional investors held Gritstone bio, Inc. Common Stock (GRTS) as of Q1 2019, up from 52 in Q4 2018.
- Funds reported $244M of Gritstone bio, Inc. Common Stock stock for Q1 2019, down 12% quarter-over-quarter.
- 10 funds opened new Gritstone bio, Inc. Common Stock positions in Q1 2019 and 8 closed out, a net change of +2 holders.
- The largest Gritstone bio, Inc. Common Stock buyer in Q1 2019 was Casdin Capital, an estimated $5.35M added.
- The largest Gritstone bio, Inc. Common Stock seller in Q1 2019 was PFM Health Sciences, an estimated $8.43M sold.
Based on aggregated 13F filings for Q1 2019.